K
Kamil Lisek
Researcher at AREA Science Park
Publications - 11
Citations - 821
Kamil Lisek is an academic researcher from AREA Science Park. The author has contributed to research in topics: Mutant & Breast cancer. The author has an hindex of 7, co-authored 9 publications receiving 624 citations. Previous affiliations of Kamil Lisek include International Centre for Genetic Engineering and Biotechnology & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
Nuclear architecture dictates HIV-1 integration site selection
Bruna Marini,Attila Kertész-Farkas,Hashim Ali,Bojana Lucic,Bojana Lucic,Kamil Lisek,Kamil Lisek,Lara Manganaro,Lara Manganaro,Sándor Pongor,Sándor Pongor,Roberto Luzzati,Alessandra Recchia,Fulvio Mavilio,Mauro Giacca,Marina Lusic,Marina Lusic +16 more
TL;DR: It is shown that HIV-1 integration occurs in the outer shell of the nucleus in close correspondence with the nuclear pore, indicating that nuclear topography is an essential determinant of the HIV- 1 life cycle.
Journal ArticleDOI
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
Dawid Walerych,Kamil Lisek,Kamil Lisek,Roberta Sommaggio,Silvano Piazza,Yari Ciani,Emiliano Dalla,Katarzyna Rajkowska,Katarzyna Gaweda-Walerych,Katarzyna Gaweda-Walerych,Eleonora Ingallina,Eleonora Ingallina,Claudia Tonelli,Marco J. Morelli,Angela Amato,Vincenzo Eterno,Alberto Zambelli,Antonio Rosato,Bruno Amati,Bruno Amati,Jacek R. Wiśniewski,Giannino Del Sal,Giannino Del Sal +22 more
TL;DR: Combining the mutant p53-inactivating agent APR-246 (PRIMA-1MET) with the proteasome inhibitor carfilzomib is effective in overcoming chemoresistance in triple-negative breast cancer cells, creating a therapeutic opportunity for treatment of solid tumours and metastasis with mutant p53.
Journal ArticleDOI
Mechanical cues control mutant p53 stability through a mevalonate-RhoA axis
Eleonora Ingallina,Giovanni Sorrentino,Rebecca Bertolio,Kamil Lisek,Alessandro Zannini,Luca Azzolin,Luisa Ulloa Severino,Luisa Ulloa Severino,Denis Scaini,Denis Scaini,Miguel Mano,Miguel Mano,Fiamma Mantovani,Antonio Rosato,Silvio Bicciato,Stefano Piccolo,Giannino Del Sal +16 more
TL;DR: The results provide evidence for an unpredicted layer of mutant p53 regulation that relies on metabolic and mechanical cues and is protected from degradation in response to matrix stiffness in a manner dependent on RhoA geranylgeranylation and actomyosin dynamics.
Journal ArticleDOI
Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.
Kamil Lisek,Elena Campaner,Elena Campaner,Yari Ciani,Dawid Walerych,Dawid Walerych,Giannino Del Sal,Giannino Del Sal +7 more
TL;DR: It is shown that thioredoxin (TXN) is a mutant p53-activated NRF2 target with pro-survival and pro-migratory functions in breast cancer cells under oxidative stress, while heme oxygenase 1 (HMOX1) isA mutant p 53-repressed target displaying opposite effects.
Journal ArticleDOI
Mutant p53: One, No One, and One Hundred Thousand
TL;DR: A number of studies on Mutant p53 are discussed, underlining the advantages and disadvantages of alternative experimental approaches that have been used to describe the numerous mutant p53 gain-of-function activities.